Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Quent Capital LLC

Quent Capital LLC decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 475 shares of the pharmaceutical company’s stock after selling 38 shares during the quarter. Quent Capital LLC’s holdings in Vertex Pharmaceuticals were worth $211,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VRTX. Brighton Jones LLC increased its stake in Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after acquiring an additional 579 shares during the last quarter. NBC Securities Inc. acquired a new stake in Vertex Pharmaceuticals during the first quarter worth $167,000. RFG Advisory LLC increased its stake in Vertex Pharmaceuticals by 12.1% during the first quarter. RFG Advisory LLC now owns 757 shares of the pharmaceutical company’s stock worth $367,000 after acquiring an additional 82 shares during the last quarter. Chesley Taft & Associates LLC purchased a new position in shares of Vertex Pharmaceuticals during the first quarter worth $236,000. Finally, Foster Group Inc. purchased a new position in shares of Vertex Pharmaceuticals during the first quarter worth $255,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $403.30 on Friday. The business’s 50-day simple moving average is $399.12 and its 200-day simple moving average is $442.50. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The stock has a market capitalization of $103.40 billion, a P/E ratio of 28.83 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the previous year, the firm earned ($12.83) earnings per share. The business’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs bought 5,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research analyst reports. Stifel Nicolaus lowered their price target on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research report on Tuesday, August 5th. Guggenheim lowered their price target on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Evercore ISI lowered their price target on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research report on Thursday, September 11th. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. Finally, Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price target for the company in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $493.81.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.